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Abstract
Background: Gastric cancer can progress from a chronic inflammation of the gastric mucosa resulting from 
Helicobacter pylori infection that activates the inflammatory response of the host. Therefore, polymorphisms in genes 
involved in the inflammatory response, such as inducible nitric oxide synthase (NOS2), have been implicated in gastric 
carcinogenesis. The aim of this study was to evaluate the association of NOS2 polymorphisms Ser608Leu (rs2297518) in 
exon 16, -954G/C and -1173C/T, both in the promoter region, with gastric cancer and chronic gastritis and the 
association of cancer with risk factors such as smoking, alcohol intake and H. pylori infection.
Methods: We conducted a population-based case-control study in 474 Southeast Brazilian individuals (150 with 
gastric cancer, 160 with chronic gastritis, and 164 healthy individuals), in which we performed NOS2 genotyping by 
PCR-RFLP.
Results: SNP Ser608Leu was not associated with risk of chronic gastritis or gastric cancer. The polymorphic allele -1173T 
was not found in the studied population. However, the frequency of -954GC+CC genotypes was significantly higher (p 
< 0.01) in the cancer group (48.7%) than in both the gastritis (28.1%) and the control (29.9%) groups. Multivariate 
logistic regression showed that the NOS2 SNP -954G/C was associated with higher risk of gastric cancer (OR = 1.87; 95% 
CI = 1.12-3.13). We also observed an association with risk factors such as smoking and alcohol intake in both the gastric 
cancer (OR = 2.68; 95% CI = 1.58-4.53; OR = 3.60; 95% CI = 2.05-6.32, respectively) and the chronic gastritis (OR = 1.93; 
95% CI = 1.19-3.13; OR = 2.79; 95% CI = 1.55-5.02, respectively) groups. This is the first report of increased risk of gastric 
cancer in association with the -954G/C polymorphism. These findings show that several polymorphisms in the 
promoter region of the NOS2 gene may contribute to the susceptibility to gastric cancer.
Conclusions: Polymorphism NOS2 -954 G/C, along with alcohol intake and tobacco smoking, is associated with gastric 
cancer. However, the NOS2 Ser608Leu polymorphism was not associated with gastric carcinogenesis. The NOS2 -1173C/
T polymorphism was absent in the studied population.
Background
Gastric cancer, the fourth most common cancer in the
world [1], is characterized as a multifactorial disease that
results from individual genetic predisposition and expo-
sure to environmental factors. Among the latter, the most
strongly associated are Helicobacter pylori infection, diet,
smoking and drinking [2]. In Brazil, gastric cancer ranges
fourth in incidence and mortality, and an estimate of
about 21,500 new cases was made for 2010 [3].
The H. pylori bacterium is the most important etiologi-
cal factor related to chronic gastritis, which is a preneo-
plastic lesion, and gastric cancer [4,5]. Furthermore, it is
present in 90% of all patients with chronic gastritis affect-
ing the antrum [6]. H. pylori-induced gastric cancer occur
through multi-step process that develops from active gas-
tritis, to gastric atrophy, intestinal metaplasia, dysplasia,
and finally to carcinoma [7]. This process consists of
three major steps, characterized as H. pylori infection,
gastric atrophy development, and carcinogenesis, which
in each step, genetic traits interacting with lifestyle may
influence the process [8]. Moreover it is assumed that
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several polymorphisms are involved in those steps, such
as polymorphisms influencing gastric acid inhibition and
innate immune response attenuation in H. pylori infec-
tion step; polymorphisms pertaining to the signal trans-
duction in the step of gastric atrophy, and yet other
polymorphisms related to final step of gastric carcino-
genesis [8].
The inflammatory response to infection by H. pylori is
an oxidative process originated by phagocytic cells that
can lead to gastric injury [9]. This process is triggered by
bacterial lipopolysaccharides, cytokines and products
from the bacterial wall, inducing nitric oxide (NO) syn-
thesis and resulting in reactive nitrogen species [10]. The
main role of the NO production by host defense cells is to
cause damage to the pathogen DNA, so it has antibacte-
rial, antiviral and antitumoral properties [11].
NO is produced by the iNOS (inducible nitric oxide
synthase) enzyme that is expressed by macrophages and
neutrophils in gastric mucosa as part of the host response
to the H. pylori infection, therefore increasing the pro-
duction of NO, which has been associated to gastric car-
cinogenesis [12]. It has been speculated that increased
levels of NO can damage host cell DNA, cause tissue inju-
ries [13] and increase cell proliferation [14]. In addition,
increased iNOS expression has been observed in patients
with chronic inflammatory diseases [15], ulcer and gastri-
tis [12], and solid tumors [16].
The iNOS enzyme is encoded by gene NOS2, and sev-
eral SNP's (Single Nucleotide Polymorphisms) were
described in it, such as the C/T substitution in exon 16
(rs2297518), which results in an amino acid substitution
(Ser608Leu) [17], and -954G/C and -1173C/T, both in the
promoter region of the gene that is linked to increased
enzyme expression, resulting in higher NO production
[18-23].
The Ser608Leu polymorphism was studied in a Spanish
population [24], in reflux esophagitis, Barrett's esopha-
gus, and esophageal adenocarcinoma in Caucasian sub-
jects [25], and in prostatic cancer in non-Hispanic
Caucasians and African-Americans [26].
Only one study reported the Ser608Leu polymorphism
to be associated with gastric cancer among subjects with
a history of smoking and alcohol intake [17], while poly-
morphisms -954G/C and -1173C/T have been associated
with inflammatory processes such as malaria in popula-
tions of Tanzania [18], Gabon [19], Kenya [20] and Ghana
[23], and osteomyelitis in Spanish subjects [27].
T o  o u r  b e s t  k n o w l e d g e ,  h o w e v e r ,  p o l y m o r p h i s m s  -
954G/C and -1173C/T have not been studied in gastric
cancer, and no allele or genotype frequencies are estab-
lished for the Brazilian population for any of the referred
SNPs. It is well accepted that both polymorphisms in the
NOS2 promoter region cause overproduction of NO, sug-
gesting that they might be observed in other diseases in
which high NO levels are demonstrated, like in gastric
carcinogenesis.
Inflammation has been recognized as a critical compo-
nent in cancer progression. Several cancers arise from
infection sites, chronic irritation and inflammation
[28,29]. It is therefore reasonable to speculate that the
genes involved in inflammatory host response to H. pylori
infection could be relevant candidate genes to be studied
in gastric cancer susceptibility. Thus, the aim of this study
was to evaluate whether NOS2 polymorphisms Ser608Leu
in exon 16 and -954G/C and -1173C/T, both in the pro-
moter region, are associated with risk of chronic gastritis
and gastric cancer in a Brazilian population and whether
there is an association of cancer with risk factors such as
smoking, alcohol intake and H. pylori infection.
Methods
Subjects
This was a case-control study on chronic gastritis and
gastric cancer, in which a total of 474 DNA samples from
peripheral blood leukocytes were genotyped. The case
groups comprised 160 individuals (78 men and 82
women) with a histopathologically confirmed diagnosis
of chronic gastritis - CG - (Sidney System) [30], with a
mean age of 53 years (range 21-86 years), and 150 individ-
uals (114 men and 36 women) with a histopathologically
confirmed diagnosis of gastric adenocarcinoma - GA -
(Lauren's classification) [31] with a mean age of 61 years
(range 28-93 years). All subjects were recruited from the
Hospital de Base in São José do Rio Preto, SP, and from
the Pio XII Foundation in Barretos, SP, Brazil. H. pylori
infection was histologically established by the Giemsa
staining technique or by the urease test, performed at the
Pathology Services of the Hospital de Base and the Pio
XII Foundation. Results were obtained for the available
cases. The cancer-free control group (C) with no previous
history of gastric disease was composed of 164 healthy
individuals (86 men and 78 women), mainly blood
donors, with a mean age of 52 years (range 20-93 years).
Epidemiological data on the study population were col-
lected using a standard interviewer-administered ques-
tionnaire, with questions about current and past
occupation, smoking habits, alcohol intake and family
history of cancer. The National Research Ethics Commit-
tee approved this work, and written informed consent
was obtained from all individuals.
Genotyping
About 5 mL of whole blood were collected from all study
participants in sterile EDTA-coated vacutainers. DNA
was extracted according to a previous report [32], and
stored at -20°C until use for genotyping.
The PCR-RFLP (Polymerase Chain Reaction-Restric-
tion Fragment Length Polymorphism) technique was car-Jorge et al. BMC Gastroenterology 2010, 10:64
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ried out to identify the NOS2 genotype according to the
SNP features, which created a restriction enzyme recog-
nition site, according to previously established protocols
[17,18,33]. The PCR and DNA digestion conditions are
summarized in Table 1. Briefly, PCR was performed in a
total reaction volume of 25 μL, containing 2.5 μL 10×
PCR buffer, 2 μL dNTPs (1.25 μmol/L), 0.5 μL MgCl2 (25
mmol/L), 1.25 μL of each primer (25 mmol/L, Sigma.),
15.3 μL dH2O, 2 μL DNA (100 ng/μL), and 0.2 μL Taq
DNA polymerase (5 U/μL, Invitrogen). After an initial
denaturation step at 94°C for 3 min, amplification was
carried out by 35 cycles at 94°C for 30 s, at 61°C for 45 s,
and at 72°C for 75 s, followed by a final elongation cycle at
72°C for 10 min. Then, 10 μL of PCR products were
digested with 0.5 μL of the specific enzyme (range 5-10
U/°L) in a 10 μL volume including 2.5 μL 10× buffer 1
(NEB Corp.) and 7.0 μL dH2O. The products were then
electrophoresed on a 2.5% agarose gel, to allow detection
by ethidium bromide staining. In order to confirm the
veracity of the results, one confirmed polymorphic case
was used as positive control for every RFLP procedure, to
attest the good functioning of the restriction enzyme. For
the -1173C/T polymorphism, we also used another frag-
ment of the IL-1β gene that we knew had the enzyme rec-
ognition site, to verify the correct functioning of the
enzyme BccI, once we did not detect any heterozygous or
polymorphic subjects.
Statistical analysis
Fisher's exact test was used to compare the groups with
regard to genotype and allele frequencies, and the chi-
square test for determining Hardy-Weinberg equilibrium.
Multiple logistic regression models were used to deter-
mine the effects of the variables in gastric cancer and
chronic gastritis. The models included: age (reference:
<57 years old - median of the groups), gender (reference:
female), smoking habits (reference: nonsmokers), drink-
ing habits (reference: nondrinkers), and H. pylori infec-
tion (reference: H. pylori-negative). The results are shown
as odds ratios (OR) and their 95% confidence intervals
(95% CI). OR's were calculated using a dominant model
(i.e., combining heterozygotes and homozygotes for the
minor allele) for all SNP's. Statistical analyses were per-
formed using the GraphPad Instat and BioEstat computer
software programs. A probability level (p) of less that 0.05
was adopted as significance criterion.
Results
The genotype frequencies of the polymorphisms studied
here were in Hardy-Weinberg equilibrium in both cases
and control groups (data not shown). For Ser608Leu geno-
type frequencies, the comparisons between cancer and
control groups (p = 0.81) and gastritis and controls (p =
0.72) did not show any statistically significant difference.
Similarly, no significant difference was found between
gastritis and control groups for -954G/C (p = 0.81), but
Table 1: PCR-RFLP conditions for NOS2 gene polymorphisms and gene IL-1β.
Genes Primers Enzyme Time/T° Fragments Reference
NOS2
Ser608Leu
rs2297518
F: 5' - TGTAAACCAACTTCCGTGGTG - 3'
R: 5' - GTCTCTGCGGGTCTGAGAAG - 3'
Tsp509I
(10 U/μL)
16 hs/65°C
288 bp
CC:113, 175 bp
CT:113, 142 and 175 bp
TT:113, 142 bp
17
NOS2
-954G/C
F: 5' - CATATGTATGGGAATACTGTATTTCAG - 3'
R: 5' - TCTGAACTAGTCACTTGAGG - 3'
BsaI (5 U/μL)
1 h/37°C
573 bp
GG:437, 136 bp
GC: 573, 437 and 136 bp
CC: 573 bp
18
NOS2
-1173C/T
F:5' - CAAAGATCCTTGAGCTCTGA - 3'
R:5' - CAACTACATTAGGGAGAAGTTGAG - 3'
BccI
(10 U/μL)
1 h/37°C
199 bp
CC: 199 bp
CT: 199, 132 bp
TT: 132 bp
33
IL-1β F:5' - CATGTGACCTGCTCGTCAGT - 3'
R:5' - CCCTAGGGATTGAGTCCACA - 3'
BccI
(10 U/μL)
1 h/37°C
372 bp
141 and 231 bp
-
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Table 2: Genotype and allele frequencies of NOS2 polymorphisms Ser608Leu, -954G/C and -1173C/T in gastric adenocarcinoma (GA), chronic gastritis (CG), and 
control (C) groups.
Genotypes/Alleles GA
N = 150 (%)
C
N = 164 (%)
OR (95%CI) p CG
N = 160 (%)
C
N = 164 (%)
OR (95%CI) p
Ser608Leu
CC 106 (70.7) 113 (69) 0.92 (0.57-1.49) 0.81 107 (66.9) 113 (69) 1.10 (0.69-1.75) 0.72
CT 36 (24) 39 (23.8) 33 (20.6) 39 (23.8)
TT 8 (5.3) 12 (7.2) 20 (12.5) 12 (7.2)
Alleles
C 0.83 0.81 0.88 (0.59-1.32) 0.61 0.77 0.81 1.24 (0.85-1.82) 0.29
T 0.17 0.19 0.33 0.19
-954G/C
GG 77 (51.3) 115 (70.1) 2.23 (1.4-3.53) <0.01 115 (71.9) 115 (70.1) 0.92 (0.57-1.49) 0.81
GC 62 (41.3) 38 (23.2) 36 (22.5) 38 (23.2)
CC 11 (7.4) 11 (6.7) 9 (5.6) 11 (6.7)
Alleles
G 0.72 0.82 1.74 (1.19-2.53) <0.01 0.83 0.82 0.91 (0.6-1.36) 0.68
C 0.28 0.18 0.17 0.18
-1173C/T
CC 150 (100) 164 (100) ND ND 160 (100) 164 ND ND
CT 0 (0) 0 (0) 0 (0) 0 (0)
TT 0 (0) 0 (0) 0 (0) 0 (0)
Alleles
C 1 1N D N D 1 1N D N D
T0 0 0 0
N, Number of individuals; OR, Odds Ratio; CI, Confidence Interval; P, probability; ND, not done.Jorge et al. BMC Gastroenterology 2010, 10:64
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there was a statistically significant difference between the
cancer and the control group (p < 0.01), due to the higher
frequencies of genotypes -954GC and -954CC in the gas-
tric cancer group (Table 2). Genotypes -1173CT and -
1173TT were absent in the studied population.
We also compared the genotype frequencies between
the cancer and the gastritis groups (data not shown). No
significance was found for Ser608Leu (p = 0.54), but for -
954G/C there was a statistically significant difference
between the groups (p < 0.01), due to higher frequencies
of genotypes -954GC and -954CC in the gastric cancer
group.
The potential associations between the distributions of
NOS2 genotypes and exposure to risk factors for gastric
cancer and chronic gastritis are presented in Table 3. In
the gastric cancer group, the data show that male gender
(OR = 1.79; 95% CI = 1.02-3.15; p = 0.04), age above 57
years (OR = 2.94; 95% CI = 1.77-4.90; p < 0.01), smoking
habit (OR = 2.68; 95% CI = 1.58-4.53; p < 0.01), alcohol
intake (OR = 3.60; 95% CI = 2.05-6.32; p < 0.01), and poly-
morphism -954G/C (OR = 1.87; 95% CI = 1.12-3.13; p =
0.01) were associated with a higher susceptibility to
developing this neoplasm. The comparison between the
gastritis and the control group showed that none of the
polymorphisms were associated with chronic gastritis,
and that male gender (OR = 0.52; 95% CI = 0.31-0.88; p =
0.01) had a protective role in the development of gastritis.
Moreover, smoking habit (OR = 1.93; 95% CI = 1.19-3.13,
p < 0.01) and alcohol intake (OR = 2.79; 95% CI = 1.55-
5.02; p < 0.01) increased the risk for gastritis. For individ-
uals tested for H. pylori infection (65 with gastric cancer
and 125 with gastritis), statistical analysis showed that H.
pylori-positive infection (OR = 3.20; 95% CI = 1.58-6.48,
p < 0.01) increased the chance of developing gastritis
(data not shown).
Discussion
NOS2 polymorphisms have been studied in several types
of diseases, including malaria [18-20,23], diabetes [34],
rheumatoid arthritis [35], osteomyelitis [36] and asthma
[33], where NO production has been implicated in the
disease pathogenesis. However, the role of NOS2  pro-
moter region variants -954G/C and -1173C/T and of the
Ser608Leu substitution in exon 16 in gastric carcinogene-
Table 3: Distribution of risk factors, genotypes of NOS2 polymorphisms Ser608Leu and -954G/C, and odds ratios (OR) for 
gastric adenocarcinoma (GA), chronic gastritis (CG), and control (C) groups.
Variables GA × C CG × C
GA/C
N
OR (95%CI) p CG/C
N
OR (95%CI) p
Gender
Female 36/78 Reference 82/78 Reference
Male 114/86 1.79 (1.02-3.15) 0.04 78/86 0.52 (0.31-0.88) 0.01
Age
<57 years 42/96 Reference 91/96 Reference
≥57 years 108/68 2.94 (1.77-4.90) <0.01 69/68 1.03 (0.64-1.65) 0.88
Smoking
Nonsmokers 43/103 Reference 73/103 Reference
Smokers 107/61 2.68 (1.58-4.53) <0.01 87/61 1.93 (1.19-3.13) <0.01
Alcohol
Nondrinkers 65/132 Reference 100/132 Reference
Drinkers 85/32 3.60 (2.05-6.32) <0.01 60/32 2.79 (1.55-5.02) <0.01
Ser608Leu
CC 106/111 Reference 108/111 Reference
CT+TT 44/53 1.19 (0.69-2.08) 0.51 52/53 1.12 (0.68-1.83) 0.64
-954G/C
GG 77/112 Reference 116/112 Reference
GC+CC 73/52 1.87 (1.12-3.13) 0.01 44/52 0.83 (0.50-1.38) 0.48
N, Number of individuals; OR, Odds Ratio; CI, Confidence Interval; P, probability.Jorge et al. BMC Gastroenterology 2010, 10:64
http://www.biomedcentral.com/1471-230X/10/64
Page 6 of 8
sis is still unclear. Therefore, in the present study, we
investigated whether NOS2  polymorphisms affect the
risk of developing gastric cancer and chronic gastritis in a
Brazilian population. To our best knowledge, this is the
first study that demonstrates an association of polymor-
phism -954G/C with risk of gastric cancer. Variant
Ser608Leu was not associated with susceptibility to
chronic gastritis and gastric cancer, and the polymorphic
allele -1173T was not found in the population studied
here.
Johannesen et al. [37] showed that the Ser608Leu poly-
morphism in exon 16 was one of the most frequent SNP's
among 10 polymorphisms of the human NOS2 gene iden-
tified in a Danish population. These authors observed an
association of this SNP with increased risk for a subset of
type 1 diabetes in HLA DR3/4-positive individuals. The
few studies that investigated the role of the Ser608Leu
polymorphism in the risk of developing diseases related
to an inflammatory process have shown conflicting
results. For instance, Shen et al. [17] found a significant
association between this polymorphism and the risk of
gastric cancer only in patients with a history of smoking
habit or alcohol intake. On the other hand, Canzian et al.
[36] observed an association between the Ser608Leu poly-
morphism and atrophic gastritis, while Holla et al. [33]
found this polymorphism to be associated with suscepti-
bility to asthma.
The amino acid affected by this SNP is located in the
catalytic domain of the protein, but the amino acid sub-
stitution is a conservative one, once it involves two amino
acids with similar properties [36]. Canzian et al. [36] sug-
gest that there is no selective pressure against either
allele, and therefore the SNP does not result in a drastic
change of function. However, the C>T substitution in the
NOS2 gene may lead to a more activated iNOS in the tar-
get cells, finally elevating NO to a higher level [33].
In our study, we observed significantly higher frequen-
cies of genotypes -954GC and -954CC in the gastric can-
cer group and also of risk factors such as smoking and
alcohol intake compared to the healthy individuals. The
relationship of drinking and smoking with iNOS activity
has been reported previously. Alcohol consumption
enhances neutrophil NO production via  activation of
iNOS, leading to neutrophil apoptosis [38]. In turn, etha-
nol oxidation generates acetaldehyde, which presents car-
cinogenic effects, since it interferes with many DNA
synthesis and repair sites, leading to tumor development
[39].
Smoking is a risk factor for gastric cancer because the
chloroform and ethanol present in cigarettes act as cellu-
lar proliferation stimulators, besides increasing angiogen-
esis, VEGF (Vascular Endothelial Growth Factor) levels
and the development of tumors. Furthermore, it has been
shown that nicotine increases the activity of matrix met-
alloproteinases 2 and 9 and the protein expression of
plasminogen activators such as urokinase-type plasmino-
gen activator and its receptor, which are indicators of
invasion and migration processes [40].
In the present study, H. pylori infection was observed in
association only in the chronic gastritis group. The
reduced number of individuals with an available H. pylori
diagnosis in both the cancer and the gastritis groups may
have led to some loss of statistical efficiency. Therefore, a
larger sample is required to achieve greater statistical pre-
cision.
The -954C variant has a limited worldwide distribution
[19], and its different frequency in mild versus severe
malaria cases has led many authors to assume that the -
954G/C mutation may play a role in innate immunity
against malaria. Kun et al. [19] found higher frequencies
of this polymorphism in malaria patients from Central
Africa but not in German blood donors, and a lower fre-
quency in samples from Southeast Asia (2%-4%). Simi-
larly, Levesque et al. [18] observed an increased
frequency of the same polymorphism in Tanzanian chil-
dren with malaria (15%), while it was reduced in black
Americans (6%) and absent in white Americans. In con-
trast, none of both polymorphisms, -954G/C and -
1173C/T, was present in either a Papua New Guinea pop-
ulation with exposure to malaria [41] or in Czech asthma
patients [33], which is in agreement with previous reports
on Caucasian populations [18,27,36,41-43] where both
polymorphisms were absent and seem to be ethnic-spe-
cific for the African population.
As for genotypes -1173CT and -1173TT, they were also
absent in our study, but these polymorphisms are
reported to be mainly prevalent in East African popula-
tions [43], as found in association with protection from
malaria in Tanzanian and Kenyan children [20]. Boutilis
e t  a l .  [ 4 1 ]  o b s e r v e d  h i g h e r  e x p r e s s i o n  o f  i N O S  w h e n
either allele -954C or -1173T were present, and it was
hypothesized that the substitution of -1173C/T could
create a new sequence recognition site for the GATA-1 or
GATA-2 transcription factors and consequently an
increased degree of transcription. An alternative hypoth-
esis would be that the -1173 C/T polymorphism disrupts
the binding of a transcription repressor at this site [20].
It is important to highlight the fact that the three poly-
morphisms studied here increase iNOS activity, thus
resulting in high NO production, which leads to the for-
mation of reactive nitrogen species [10]. As a result, many
oncogenic mutations may occur by mechanisms such as
hOGG1 repair enzyme inhibition and inactivation of
apoptosis through pro-apoptotic nitrosilation of proteins
like p53 and caspases [44]. Moreover, an increased iNOS
expression is related to the angiogenesis process [12].
When there are gastric injuries caused by H. pylori
infection, the iNOS enzyme can play an important role inJorge et al. BMC Gastroenterology 2010, 10:64
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carcinogenesis, once the gastritis can persist for years and
NOS2 stays active during all the process. Due to a positive
feedback, the levels of NO increase up to a point that is
highly toxic to the gastric cells, not only to the pathogen
[44].
The Brazilian population displays great genetic hetero-
geneity as a consequence of high miscegenation during
colonization, resulting mainly from the mating between
natives Amerindians, African slaves (coming mostly from
Africa's West Coast, such as Angola and the north of the
Gulf of Guinea, and less from the counter-coast, such as
Mozambique) and Europeans [45], which explains the
differences from other studied populations. Gonçalves et
al. [46] showed that most white Brazilians display high
proportions of African and Amerindian mtDNA lineages,
because of sex-biased genetic admixture with Europeans.
So, the Brazilian population can have both African and
European genetic components, which could explain the
presence or absence of several polymorphisms in our
study. Levesque et al. [18] also reported differences in
NOS2  promoter polymorphisms and malaria severity
between populations of Tanzania (East Africa), Gabon
(Central Africa) and Gambia (West Africa), suggesting
differences in the genetic background of these popula-
tions.
Thus, the distribution of genetic polymorphisms can
vary among populations, depending on factors such as
selective pressure, founder effect, migration, population
sub-sampling and various socio-cultural factors that
influence purely random mating [41]. Finding major dif-
ferences among populations is therefore not surprising
and indicates that the results of a study conducted in a
given population should not be extrapolated to others. In
addition, considering the large extension of Brazil, there
may be differences in genotype distribution from one
region to another due to different contributions of the
three ethnic groups to the composition of the populations
of these regions. Therefore, it is important that these
findings are also investigated in other Brazilian popula-
tions.
Conclusions
In conclusion, our study showed for the first time an
association between the SNP in the NOS2 -954G/C pro-
moter region and risk of gastric cancer, as well as an asso-
ciation with smoking and alcohol consumption in both
gastric cancer and chronic gastritis in the Southeast Bra-
zilian population evaluated. We, however, did not find
any evidence of an association between the NOS2 poly-
morphism Ser608Leu in exon 16 and risk of gastric cancer
or chronic gastritis, and did not detect the variant -
1173T. Therefore, these results evidence that several
NOS2 polymorphisms are associated with susceptibility
to gastric cancer and emphasize the importance of such
studies in populations of different ethnic extraction.
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